NEW YORK, Oct. 21-Lion Bioscience expects its revenues for the year to fall by as much as 25 percent from last year's totals, the company said today. In a statement released this morning, CEO Friedrich von Bohlen blamed non-cash write-offs, a shift from in-house drug discovery, and the general malaise in the life sciences industry for the shortfall.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.